InGenious Targeting Laboratory Enters New Decade with New GeneTargeting.com

inGenious Targeting Laboratory Enters New Decade with New GeneTargeting.com Stony Brook, New York, USA -- inGenious Targeting Laboratory (iTL) launched a new website today, www.genetargeting.com, marking the first release of its brand and priorities for the new decade. In the 12th year of business, iTL continues it's focus and commitment to delivering an exceptional service and customer experience through every customer interaction. “We will always be ready to answer the phone with a friendly greeting to our customers,” states Paul Sheiffele, President and COO of the company. “but providing a web portal to information and resources that our customers find useful and can use to communicate with us is a growing point of value.” The launch of the new website is the first step in a series of improvements. Subsequent work will aim to incorporate and build out new content and tools which are helpful and industry relevant. As the focus on custom and novel mouse models pushed the limits of existing technology, iTL developed a scientific platform to bring more capabilities to customers. Now it is taking the same pathway with its web portal. “We have focused heavily on building and maintaining relationships with our customers in academia, research hospitals, pharma and biotech.” recalls Sheiffele. “Our website will become an extension of these important relationships, and I am very much looking forward to working with our customers to make it happen.” The next phase and release of web development and resources is scheduled for the third quarter of 2010. About inGenious Targeting LaboratoryinGenious Targeting Laboratory (iTL) is a global provider of gene targeting and custom mouse model production and services. iTL has delivered nearly one thousand successful custom mouse models to investigators, organizations and companies in 41 US states and 32 countries on 6 continents. iTL serves academic and medical institutes, government research centers, and pharmaceutical and biotechnology companies. Customers retain full intellectual property rights to their projects. A full range of project capabilities are available including conventional knockout, conditional knockout, knockin, reporter genes, knockin human/murine cDNAs, targeted transgenic models, as well as novel approaches for custom models. Full-service customer projects are initiated immediately upon completion of design parameters and progress to completion on-site. iTL also collaborates with Charles River Laboratories International, Inc. to provide customers with specialized animal husbandry services. iTL is a privately held service and customer focused biotechnology company founded and located in Stony Brook, New York, USA. www.genetargeting.com

Terms | Privacy | Contact us | Site Map | Links

Sitemap 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61
62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91
92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121
122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151
152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181
182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211
212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241
242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271
272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301
302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331
332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361
362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391
392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421
422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451
452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481
482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511
512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541
542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571
572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601
602 603 604 605 606 607 608 609 610 611 612 613 614

This website disclaims any content found in these news releases or articles. Issuers of news releases or articles are solely responsible for the accuracy of their content. If you have any questions regarding information in these news releases, please contact the issuers of the press releases.
© Copyright @ 2005. All rights Reserved. Use of our service is protected by our Privacy policy and Terms of Service.